Simple Pharma acquires Testavan® and Vitaros®

St-Prex/London — Tuesday 16th February 2021 — Ferring Pharmaceuticals divests its full rights for Testavan® and Vitaros® to Simple Pharma.

By divesting its rights to Simple Pharma on this transaction, Ferring is able to focus on areas of high unmet need to bring the most value to patients and healthcare professionals.

  • Testavan® (transdermal testosterone gel 2%) is a testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. Launched in 2018, Testavan® is formulated with F.A.S.T. (Ferring’s Advanced Skin Technology) absorption to enhance bioavailability of testosterone through the skin, and is administered using a hands-free applicator that may lower the risk of transference of testosterone skin residue from the patient to others. Testavan® is sold in over 20 countries worldwide, with plans to launch in a further 10+ countries.
  • Vitaros® (alprostadil cream) is the only topical cream that treats Erectile Dysfunction (ED). The treatment is a first line alternative for ED patients and especially patients who prefer local treatment or may not be candidates for oral PDE-5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) due to medical constraints or concomitant medications. Vitaros® is sold in more than 15 countries worldwide including through its licensing partners.

“This is a landmark acquisition for Simple Pharma and demonstrates the relevance of our positioning as a go-to divestment partner for large pharmaceutical companies. We are looking forward to growing Testavan® and Vitaros® into a thriving men’s health franchise, while continuing to help pharmaceutical companies simplify their portfolio. Our digital operations platform allows us to integrate, manage, market, and grow products of any size, maintaining and expanding patient access to medicines.”

Nicolas Vennin & Charlie Bryant, Co-founders of Simple Pharma

“In an effort to streamline its focus on the highest unmet needs to bring the most value to patients and healthcare professionals, Ferring has revisited its broader urology portfolio and decided that Simple Pharma is the right company to take Testavan® and Vitaros® forward as part of their commitment to establishing a differentiated men’s health franchise. We will be working closely with Simple Pharma during the transition period to ensure continuity of supply for patients, and to ensure a smooth handover of the final regulatory authorisations.

Jan Peutzfeldt, Senior Vice President, Global Marketing & Business Development

The terms of the transaction are not disclosed.

About Simple Pharma

Simple Pharma is a pharmaceutical company founded in 2019 that specialises in the acquisition, integration, and commercialisation of products being divested by other pharmaceutical companies. This landmark acquisition of two established men’s health brands, Testavan® and Vitaros®, expands Simple Pharma’s distribution footprint to more than 30 countries worldwide.

Simple Pharma’s mission is to improve patient access to medicines by focusing on pharma operations. The team will seek to build on Ferring’s success in existing countries and launch in new territories to reach a wider patient and prescriber audience.

Learn more at, or connect with us on LinkedIn.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in speciality areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

Media enquiries

If you have any questions or would like further information, please contact:

Join our newsletter

Stay up to date with news and insights